Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Axitinib Stories

2010-11-17 08:30:00

BURLINGTON, Mass., Nov. 17, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds although the pancreatic cancer drug market will remain relatively flat through 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan, the first-line patient population will experience a dynamic change in treatment practice owing to increased uptake of the cytotoxic regimen, FOLFIRINOX* and...

2010-06-29 08:00:00

WALTHAM, Mass., June 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, robust 4.1 percent annual growth in the renal cell carcinoma drug market will be driven primarily by the uptake of GlaxoSmithKline's Votrient/Patorma, the launches of premium-priced emerging therapies and an increase in diagnosed incidence and treatment rates. The Pharmacor 2010 findings from the topic...

2010-05-26 06:30:00

CALGARY, May 26 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center in San Antonio (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced pancreatic cancer. The Principal Investigator is Dr. Monica Mita of the CTRC....

2010-05-20 07:00:00

NEW YORK, May 20 /PRNewswire-FirstCall/ -- Pfizer Oncology (NYSE: PFE) will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology (ASCO) meeting in Chicago from June 4-8. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) "Pfizer Oncology is committed to applying discoveries from cancer...

2010-04-22 07:00:00

BOULDER, Colo., April 22 /PRNewswire/ -- Clovis Oncology, Inc. and Ventana Medical Systems, Inc. announced today that they have entered into a collaboration agreement for the development of a human equilibrative nucleoside transporter 1 (hENT1) immunohistochemistry (IHC) assay, which will be used in Clovis' CO-101 clinical trials to identify patients with low level tumor expression of hENT1 protein. If CO-101 is successfully developed, Clovis Oncology will submit new drug applications...

2010-02-04 07:00:00

WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that AVEO Pharmaceuticals' tivozanib, which is expected to launch in 2013 in the United States and Europe and in 2016 in Japan, will garner sales of up to $100 million by 2018 in the renal cell carcinoma drug market. The Pharmacor 2010 findings from the topic entitled Renal Cell Carcinoma show that interviewed thought leaders...

2009-09-14 07:00:00

WALTHAM, Mass., Sept.14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class. The new Pharmacor...

2009-03-25 06:30:00

CALGARY, March 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced the completion of patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects of intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced cancers including breast, and head and neck. The principal investigators are Dr. Johann de Bono of The Royal Marsden NHS Foundation Trust and The Institute of...

2008-09-30 09:00:17

Pfizer Inc today provided the latest update to its development pipeline, showing significant progress in achieving the company's growth, productivity and performance goals. The pipeline now includes 114 programs, from Phase 1 through Registration. The number in late-stage (Phase 3) development has grown from 16 to 25 over the past six months. In total, 31 programs advanced to the next stage of development; 13 were discontinued; and one was withdrawn from registration. The majority...

2008-09-11 09:00:09

AmpliMed, a cancer therapeutics company, has entered into a license agreement with Korean-based pharmaceutical company Handok Pharmaceuticals for exclusive rights to its investigational cancer therapeutic Amplimexon in Korea. Under terms of the agreement, Handok will receive marketing and distribution rights to all cancer indications for Amplimexon in Korea and will pay AmpliMed an up-front fee plus additional payments based upon the achievement of certain development and regulatory...